Seres Therapeutics (MCRB) Free Cash Flow (2014 - 2026)
Seres Therapeutics (MCRB) posted Free Cash Flow of -$16.4 million for Q1 2026, down 11.0% sequentially from -$14.7 million in Q4 2025, and down 160.92% YoY from $26.9 million in Q1 2025.
Seres Therapeutics (MCRB) Free Cash Flow (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Free Cash Flow for 13 years, with the latest figure at -$16.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 160.92% year-over-year to -$16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.4 million (up 51.05% YoY) and the FY2025 annual result came in at $865000.0, up 100.58% from the prior year.
- Free Cash Flow declined to -$16.4 million in Q1 2026 per MCRB's latest filing, from -$14.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $61.6 million in Q2 2023 and troughed at -$77.5 million in Q1 2023.
- A 5-year average of -$30.6 million and a median of -$38.6 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow surged 213.28% in 2023, then tumbled 164.62% in 2024.
- Over 5 years, Free Cash Flow stood at -$56.4 million in 2022, then advanced by 16.34% to -$47.1 million in 2023, then rose by 18.14% to -$38.6 million in 2024, then surged by 61.81% to -$14.7 million in 2025, then retreated by 11.0% to -$16.4 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$16.4 million, -$14.7 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - | -22.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.39 Mn |
| Jun 30, 2026 | -22.39 Mn |
| Mar 31, 2026 | -16.36 Mn |
| Mar 31, 2026 | -16.36 Mn |
| Dec 31, 2025 | -14.74 Mn |
| Dec 31, 2025 | -14.74 Mn |
| Sep 30, 2025 | 2.20 Mn |
| Sep 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | -13.45 Mn |
| Jun 30, 2025 | -13.45 Mn |
| Mar 31, 2025 | 26.86 Mn |
| Mar 31, 2025 | 26.86 Mn |
| Dec 31, 2024 | -38.59 Mn |
| Dec 31, 2024 | -38.59 Mn |
| Sep 30, 2024 | -34.97 Mn |
| Sep 30, 2024 | -34.97 Mn |
| Jun 30, 2024 | -39.81 Mn |
| Jun 30, 2024 | -39.81 Mn |
| Mar 31, 2024 | -35.24 Mn |
| Mar 31, 2024 | -35.24 Mn |